Stay updated on TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial
Sign up to get notified when there's something new on the TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial page.

Latest updates to the TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now shows an updated Revision: v3.6.5. Several study documents and related metadata were removed from the Study Documents section, indicating cleanup of archived materials.SummaryDifference17%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision: v3.6.4 was added and Revision: v3.6.3 was removed. This reflects a site version update for the page rather than a modification to the study information.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision: v3.6.3 is now shown on the page, replacing v3.6.2. This indicates a minor page update that does not modify the study details.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page revision label changed from v3.6.0 to v3.6.2, indicating a small update to the page. No trial information or patient-facing content appears to be modified.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page now displays a recruitment-status note ('No longer looking for participants') and adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study). The label for the section 'Intervention / Treatment' was changed to 'Intervention/Treatment', and the revision line updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check73 days agoChange DetectedA new page revision entry, v3.5.5, was added and the previous v3.5.4 entry removed, updating the page's revision history to reflect the latest version.SummaryDifference0.1%

Stay in the know with updates to TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial page.